Control of Moderate or Severe Asthma With 160, 320 and 640 mcg Ciclesonide/Day. A One-year Randomised, Double-blind, Multicenter Trial.
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Ciclesonide (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms CONTRAST
- Sponsors Takeda
- 06 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 May 2012 Company (Takeda Global Research and Development Center, Inc) added as reported by ClinicalTrials.gov.